Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cipla
Boehringer Ingelheim
McKinsey
Express Scripts
Farmers Insurance
Johnson and Johnson
Healthtrust
AstraZeneca

Generated: April 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,545,884

« Back to Dashboard

Which drugs does patent 8,545,884 protect, and when does it expire?

Patent 8,545,884 protects GILOTRIF and is included in one NDA.

This patent has thirty-two patent family members in thirty-two countries.
Summary for Patent: 8,545,884
Title:Solid pharmaceutical formulations comprising BIBW 2992
Abstract: The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA.sub.2) in form of a powder prepared using a combined roller compaction and sieving step from BIBW 2992 MA.sub.2, intermediate blends prepared from said compacted intermediate as well as solid oral formulations providing an immediate release profile of the active substance, made from said compacted intermediate or from said intermediate blends ready for use/ingestion, e.g. capsule and tablet formulations such as uncoated or film-coated tablets prepared by direct-compression, and methods for their production.
Inventor(s): Messerschmid; Roman (Biberach, DE), Friedl; Thomas (Ochsenhausen, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:12/995,715
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form; Use;

Drugs Protected by US Patent 8,545,884

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-001 Jul 12, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-002 Jul 12, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-003 Jul 12, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,545,884

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08157800Jun 6, 2008
09160297May 14, 2009
PCT Information
PCT FiledJune 05, 2009PCT Application Number:PCT/EP2009/056944
PCT Publication Date:December 10, 2009PCT Publication Number: WO2009/147238

International Family Members for US Patent 8,545,884

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072062 ➤ Try a Free Trial
Australia 2009254574 ➤ Try a Free Trial
Brazil PI0913379 ➤ Try a Free Trial
Canada 2726472 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Citi
Deloitte
Medtronic
Daiichi Sankyo
Accenture
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.